^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Emcyt (estramustine)

    Associations
    News

    Trials

    Company:
    Nippon Shinyaku, Pfizer
    Drug class:
    Microtubule inhibitor, DNA inhibitor, Estrogen receptor agonist
    Related drugs:
    Associations
    News

    Trials

    Apply
    Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy (NCT00005847)
    Phase 2
    Eastern Cooperative Oncology Group
    Completed
    Last update posted :
    06/22/2023
    Initiation :
    04/05/2001
    Primary completion :
    07/01/2004
    BCL2
    |
    paclitaxel • vinorelbine tartrate • mitoxantrone • Emcyt (estramustine)
    Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor. (NCT02866955)
    Phase 2
    Institut de Cancérologie de Lorraine
    Completed
    Last update posted :
    03/09/2020
    Initiation :
    06/15/2011
    Primary completion :
    08/08/2014
    Completion :
    08/28/2015
    HER-2
    |
    tamoxifen • Emcyt (estramustine)
    Efficacy and Safety of Estracyt® in Metastatic Breast Cancer (NCT02853071)
    Phase 2
    Centre Hospitalier Universitaire de Besancon
    Withdrawn
    Last update posted :
    11/18/2019
    Initiation :
    01/01/2017
    Primary completion :
    01/01/2020
    Completion :
    01/01/2020
    HER-2
    |
    Emcyt (estramustine)
    Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma (NCT00038246)
    Phase 1/2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    10/31/2018
    Initiation :
    10/01/2000
    Primary completion :
    02/01/2004
    Completion :
    12/01/2004
    EGFR
    |
    paclitaxel • thalidomide • Emcyt (estramustine)